Catalysts for Keytruda

Merck & Co Inc — pembrolizumab (Phase II Trial Completion)

National Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval

KEYTRUDA (PEMBROLIZUMAB) — FDA approval